815P - Clinical outcome of metastatic endometrial carcinoma patients treated with chemotherapy: ENDOVIE, a GINECO national observational cohort study

Background

Incidence of metastatic endometrial carcinoma (EC) is increasing worldwide. Recent therapeutic innovations reinforce the need to better understand patients (pts) characteristics, treatment patterns and clinical outcome in the real-world setting.

Methods

Patients beginning 1st or 2nd line chemotherapy (chemo) during the year 2019 were included in this multicenter, retrospective cohort study and were followed until December 31, 2021 or death. Up to 9 pts were included in each of the 30 centers across France. Two hundred pts, 127 in 1st line (cohort 1) and 73 in 2nd line (cohort 2), were enrolled. Median age was 71 years (min: 39 max: 93) and 31 % were > 75 years old. Significant comorbidities included overweight (BMI > 25 kg/m²) in 49 % of pts, medically treated hypertension, diabetes mellitus and deep venous thrombosis in 28.5%, 14.5% and 11%, respectively. ECOG performance status was 2 or 3 in 12% of pts. Endometrioïd carcinoma was the most common histological subtype (62%), followed by serous carcinoma (22%) and carcinosarcoma (5%). One third of pts had a FIGO IVB disease. MMR status was available only in 34% of pts and 21% of them was deficient.

Results

In 1st line, most pts received carboplatin and paclitaxel association (79%) or other platinum-based combinations (17%). Median PFS and OS were 8.5 months (mos) (CI 95%: 6.3-10.5) and 13.2 mos (CI95%: 10.9-16.6), respectively. The presence of liver metastases was the main prognostic factor for PFS and OS. In 2nd line, data from pts in cohorts 1 (49% received 2^nd line chemo during the follow-up period) and 2 were pooled (n=135). Anthracycline and weekly paclitaxel as a single agent were used in 52% and 10%, respectively while platinum-based protocol was used in 23% of patients. Median PFS and OS were 4.0 mos (CI95%: 3.5-5.3) and 9.6 mos (CI95%: 8.3-11.8), respectively. A 3rd line of chemo was administered to 78 pts (39%): 31% received gemcitabine and 17% a platinum-based combination. Median PFS was 2.6 mos (CI95%: 2.1-4.1).

Conclusions

In this real-life cohort, metastatic EC affected older and frail women and was associated with poor overall survival despite chemo. There is an urgent need of new therapeutics.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

ARCAGY-GINECO.

Funding

MSD.

Disclosure

J. Alexandre: Financial Interests, Personal, Advisory Board: Eisai, MSD, GSK, Janssen, Pfizer; Financial Interests, Personal, Invited Speaker: Eisai, MSD, AstraZeneca, GSK, Novartis; Financial Interests, Institutional, Research Grant: Janssen, GSK, MSD; Financial Interests, Institutional, Local PI: MSD, Eisai, Agenus, GSK, Immunogen, Incyte. E. Kalbacher: Financial Interests, Personal and Institutional, Advisory Role: AstraZeneca, Eisai, GSK, Leopharma, Roche, Sanofi, Seagen, Tesaro, Viatris. B. Asselain: Financial Interests, Personal, Advisory Board: BMS, Pierre Fabre; Financial Interests, Personal, Advisory Role: AstraZeneca, Daiichi Sankyo, Gilead; Financial Interests, Personal, Training: Servier, Roche. S. Emambux: Financial Interests, Personal, Advisory Role: BMS, Eisai, Janssen; Financial Interests, Personal, Other, Travel: Pfizer, Chugai. G. Babin: Financial Interests, Personal, Advisory Role: MSD, GSK. C. Lescure: Non-Financial Interests, Personal, Other, attend congress ( ESMO 2022 ): Viatris; Non-Financial Interests, Personal, Other, attend congress ( St Paul de Vence 2022 & 2023): Lilly. P. Heudel: Financial Interests, Personal, Advisory Board: AstraZeneca, Pfizer, Novartis, Seagen, Lilly, MSD, Gilead; Financial Interests, Personal, Ownership Interest: GeodAIsics. N. Delanoy: Financial Interests, Personal, Advisory Role: GSK, Clovis Oncology, Eisai. P. Combe: Financial Interests, Personal and Institutional, Advisory Board, + Investigator: AstraZeneca, BMS, MSD, Novartis; Financial Interests, Personal, Advisory Board: Eisai, Sanofi, Daiichi Sankyo, Clovis Oncology, GSK, Amgen. F. Selle: Financial Interests, Personal and Institutional, Advisory Role, + Clinical Trial: AstraZeneca, GSK, MSD; Financial Interests, Personal, Advisory Role: Novartis, Clovis Oncology; Financial Interests, Institutional, Other, Clinical Trial: Roche, Immunogen, Incyte, Agenus. A. Hakme, L. Cagnan: Financial Interests, Personal, Full or part-time Employment: MSD. S. De Percin: Financial Interests, Personal, Invited Speaker: Eisai; Financial Interests, Personal, Advisory Board: Boehringer Ingelheim. All other authors have declared no conflicts of interest.